ATE547706T1 - Verwendung von clec1b zur bestimmung des herz- kreislauf- und thrombose-risikos - Google Patents
Verwendung von clec1b zur bestimmung des herz- kreislauf- und thrombose-risikosInfo
- Publication number
- ATE547706T1 ATE547706T1 AT08802144T AT08802144T ATE547706T1 AT E547706 T1 ATE547706 T1 AT E547706T1 AT 08802144 T AT08802144 T AT 08802144T AT 08802144 T AT08802144 T AT 08802144T AT E547706 T1 ATE547706 T1 AT E547706T1
- Authority
- AT
- Austria
- Prior art keywords
- clec1b
- thrombosis risk
- determine cardiovascular
- cardiovascular
- thrombosis
- Prior art date
Links
- 102100032529 C-type lectin domain family 1 member B Human genes 0.000 title 1
- 101000942284 Homo sapiens C-type lectin domain family 1 member B Proteins 0.000 title 1
- 208000007536 Thrombosis Diseases 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07291134A EP2048243A1 (de) | 2007-09-24 | 2007-09-24 | Verwendung von Clec1B zur Bestimmung von Herz-Kreislauf- und Thromboserisiko |
PCT/EP2008/007593 WO2009040002A1 (en) | 2007-09-24 | 2008-09-13 | Use of clec1b for the determination of cardiovascular and thrombotic risk |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE547706T1 true ATE547706T1 (de) | 2012-03-15 |
Family
ID=38765869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08802144T ATE547706T1 (de) | 2007-09-24 | 2008-09-13 | Verwendung von clec1b zur bestimmung des herz- kreislauf- und thrombose-risikos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100311053A1 (de) |
EP (3) | EP2048243A1 (de) |
JP (1) | JP2010539891A (de) |
KR (1) | KR20100059897A (de) |
CN (1) | CN101809168A (de) |
AR (1) | AR068529A1 (de) |
AT (1) | ATE547706T1 (de) |
AU (1) | AU2008303866A1 (de) |
BR (1) | BRPI0817944A2 (de) |
CA (1) | CA2700219A1 (de) |
IL (1) | IL204557A0 (de) |
MX (1) | MX2010002993A (de) |
SG (1) | SG184704A1 (de) |
TW (1) | TW200934877A (de) |
WO (1) | WO2009040002A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2269597A1 (de) * | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 ist ein wesentlicher plättchenaktivierender Rezeptor bei Hämostase und Thrombose |
US20140179766A1 (en) * | 2011-05-14 | 2014-06-26 | Royal College Of Surgeons In Ireland | Identification of thrombosis or bleeding risk in an individual with and without anti-platelet therapy |
EP2592422A1 (de) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomik-Biomarker zur Prognose von kardiosvaskulären Ergebnissen bei Patienten mit Erkrankung der Herzkranzgefäße unter Statinbehandlung |
EP2592423A1 (de) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomik-Biomarker zur Prognose von kardiosvaskulären Ergebnissen bei Patienten mit Erkrankung der Herzkranzgefäße ohne Statinbehandlung |
CN105112554B (zh) * | 2015-09-28 | 2019-03-01 | 北京泱深生物信息技术有限公司 | Clec1b基因在胆管癌诊断和治疗中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
WO2006115295A1 (en) * | 2005-04-25 | 2006-11-02 | University Of Yamanashi | Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction |
JP2007070359A (ja) * | 2005-09-06 | 2007-03-22 | Univ Of Yamanashi | 止血疾患治療用の医薬組成物 |
-
2007
- 2007-09-24 EP EP07291134A patent/EP2048243A1/de not_active Withdrawn
-
2008
- 2008-09-13 AU AU2008303866A patent/AU2008303866A1/en not_active Abandoned
- 2008-09-13 AT AT08802144T patent/ATE547706T1/de active
- 2008-09-13 US US12/679,547 patent/US20100311053A1/en not_active Abandoned
- 2008-09-13 MX MX2010002993A patent/MX2010002993A/es not_active Application Discontinuation
- 2008-09-13 JP JP2010525238A patent/JP2010539891A/ja not_active Abandoned
- 2008-09-13 CA CA2700219A patent/CA2700219A1/en not_active Abandoned
- 2008-09-13 EP EP08802144A patent/EP2195455B1/de active Active
- 2008-09-13 BR BRPI0817944 patent/BRPI0817944A2/pt not_active IP Right Cessation
- 2008-09-13 KR KR1020107006318A patent/KR20100059897A/ko not_active Application Discontinuation
- 2008-09-13 SG SG2012063285A patent/SG184704A1/en unknown
- 2008-09-13 EP EP10163295A patent/EP2233584A1/de not_active Withdrawn
- 2008-09-13 CN CN200880108448A patent/CN101809168A/zh active Pending
- 2008-09-13 WO PCT/EP2008/007593 patent/WO2009040002A1/en active Application Filing
- 2008-09-22 AR ARP080104114A patent/AR068529A1/es not_active Application Discontinuation
- 2008-09-22 TW TW097136244A patent/TW200934877A/zh unknown
-
2010
- 2010-03-16 IL IL204557A patent/IL204557A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2233584A1 (de) | 2010-09-29 |
US20100311053A1 (en) | 2010-12-09 |
CN101809168A (zh) | 2010-08-18 |
TW200934877A (en) | 2009-08-16 |
BRPI0817944A2 (pt) | 2015-05-05 |
KR20100059897A (ko) | 2010-06-04 |
AU2008303866A1 (en) | 2009-04-02 |
EP2048243A1 (de) | 2009-04-15 |
IL204557A0 (en) | 2010-11-30 |
CA2700219A1 (en) | 2009-04-02 |
EP2195455A1 (de) | 2010-06-16 |
EP2195455B1 (de) | 2012-02-29 |
AR068529A1 (es) | 2009-11-18 |
SG184704A1 (en) | 2012-10-30 |
MX2010002993A (es) | 2010-04-01 |
JP2010539891A (ja) | 2010-12-24 |
WO2009040002A1 (en) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160859T1 (hr) | Modificirani proteini rsv f i postupci njihove upotrebe | |
BRPI0920670A8 (pt) | composição nutritiva para promover o desenvolvimento e crescimento sadios | |
BRPI0907575A2 (pt) | Ligação de propriedades visuais de gráficos e células dentro de tabelas | |
DK3153526T3 (da) | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler | |
BRPI0919301A2 (pt) | aparecimento e gerenciamento de controles específicos de janela | |
FI20085760L (fi) | Muunnettu komposiittituote ja menetelmä sen valmistamiseksi | |
HK1160148A1 (en) | Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin | |
DK2259674T3 (da) | Delta-4-desaturase og anvendelse heraf i fremstillingen af flerumættedefedtsyrer | |
BRPI0913949A2 (pt) | preparação e composição de proteínas inibidoras inter-alfa a partir de sangue | |
GB2462066B (en) | Improvements in and relating to drying of water damaged buildings | |
DK2408794T3 (da) | Isolering og oprensning af vallebestanddele | |
DE602005015297D1 (de) | Verwendung von ozon zur verbesserung des knetvorgangs | |
ATE547706T1 (de) | Verwendung von clec1b zur bestimmung des herz- kreislauf- und thrombose-risikos | |
DE112008002473A5 (de) | Bestimmung der Aktivität von Proteasen | |
DE112009001910A5 (de) | Sleep determination and sleep determination method | |
BRPI0819960A2 (pt) | "biomaterial e método de preparação do mesmo" | |
GB2466466B (en) | Wear piece element and method of construction | |
FR2966076B1 (fr) | Surinjection de mat fibreux et piece obtenue | |
DK2250179T3 (da) | Lecithin-baseret sammensætning og dens anvendelse i fødevarer | |
DE602007005878D1 (de) | Verwendung von 1,2-Dihydroperillaldehyd in Geschmacksanwendungen | |
EP2292265A4 (de) | Antiangiogene molekülgruppe und ihre verwendung | |
FI20075177A0 (fi) | Vedenpoistoelementti ja metallilistan käyttö vedenpoistoelementissä | |
FI20086034A (fi) | Menetelmä jauhimen valmistamiseksi ja jauhin | |
ATE524185T1 (de) | Neue therapeutische verwendung von alfuzosine | |
ES1067969Y (es) | Monedero de euros y fracciones |